Department of Organic Chemistry, Faculty of Sciences, University of Geneva, Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Nat Commun. 2023 Jul 1;14(1):3893. doi: 10.1038/s41467-023-39657-1.
Target deconvolution of small molecule hits from phenotypic screens presents a major challenge. Many screens have been conducted to find inhibitors for the Hedgehog signaling pathway - a developmental pathway with many implications in health and disease - yielding many hits but only few identified cellular targets. We here present a strategy for target identification based on Proteolysis-Targeting Chimeras (PROTACs), combined with label-free quantitative proteomics. We develop a PROTAC based on Hedgehog Pathway Inhibitor-1 (HPI-1), a phenotypic screen hit with unknown cellular target. Using this Hedgehog Pathway PROTAC (HPP) we identify and validate BET bromodomains as the cellular targets of HPI-1. Furthermore, we find that HPP-9 is a long-acting Hedgehog pathway inhibitor through prolonged BET bromodomain degradation. Collectively, we provide a powerful PROTAC-based approach for target deconvolution, that answers the longstanding question of the cellular target of HPI-1 and yields a PROTAC that acts on the Hedgehog pathway.
从表型筛选中去除小分子命中物是一个主要挑战。已经进行了许多筛选,以寻找 Hedgehog 信号通路的抑制剂 - 该通路在健康和疾病中有许多影响 - 产生了许多命中物,但只有少数确定的细胞靶标。我们在这里提出了一种基于蛋白酶体靶向嵌合体(PROTAC)和无标记定量蛋白质组学的靶标鉴定策略。我们基于 Hedgehog 通路抑制剂-1(HPI-1)开发了一种 PROTAC,这是一种表型筛选命中物,其细胞靶标未知。使用这种 Hedgehog 通路 PROTAC(HPP),我们鉴定并验证了 BET 溴结构域是 HPI-1 的细胞靶标。此外,我们发现 HPP-9 是一种长效 Hedgehog 通路抑制剂,可通过延长 BET 溴结构域降解来实现。总之,我们提供了一种强大的基于 PROTAC 的方法,用于去除靶标,回答了 HPI-1 的细胞靶标的长期问题,并产生了一种作用于 Hedgehog 通路的 PROTAC。